Xiaoli Feng

Dr. Xiaoli Feng


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in ACS Nano
Verified
Journal Article
Closed access
YKYiyuan Kang
Yiyuan Kang
JLJia Liu
Jia Liu
SYSuhan Yin
Suhan Yin
YJYanping Jiang
Yanping Jiang
XFXiaoli Feng
Xiaoli Feng
Longquan ShaoLongquan Shao
Longquan Shao

1 June 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XCXiuwen Chen
Xiuwen Chen
MZMeiyan Zou
Meiyan Zou
SLSiquan Liu
Siquan Liu
WCWeilin Cheng
Weilin Cheng
WGWeihong Guo
Weihong Guo
XFXiaoli Feng
Xiaoli Feng
Graphene family nanomaterials (GFNs) have attracted considerable attention in diverse fields from engineering and electronics to biomedical applications because of their distinctive physicochemical properties such as large specific surface area, high mechanical strength, and favorable hydrophilic nature. Moreover, GFNs have demonstrated the ability to create an anti-inflammatory environment and exhibit antibacterial effects. Consequently, these materials hold immense potential in facilitating cell adhesion, proliferation, and differentiation, further promoting the repair and regeneration of various tissues, including bone, nerve, oral, myocardial, and vascular tissues. Note that challenges still persist in current applications, including concerns regarding biosecurity risks, inadequate adhesion performance, and unsuitable degradability as matrix materials. This review provides a comprehensive overview of current advancements in the utilization of GFNs in regenerative medicine, as well as their molecular mechanism and signaling targets in facilitating tissue repair and regeneration. Future research prospects for GFNs, such as potential in promoting ocular tissue regeneration, are also discussed in details. We hope to offer a valuable reference for the clinical application of GFNs in the treatment of bone defects, nerve damage, periodontitis, and atherosclerosis.

1 March 2014 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
XWXiangling Wang
Xiangling Wang
XFXiaoli Feng
Xiaoli Feng
JWJuandong Wang
Juandong Wang
NSNa Shao
Na Shao
CJChunyan Ji
Chunyan Ji
CZchengyun zheng
chengyun zheng
The aim of this study was to examine the hypothesis that a combination of proteasome inhibition by bortezomib and immune therapy with interleukin-12 (IL-12) can produce enhanced antitumor efficacy relative to the effects of either of these agents alone. A mouse xenograft model of myeloma was developed. The mice were randomly divided into saline control (NS), IL-12 (0.4 µg/animal; intraperitoneal), bortezomib (0.75 mg/kg; intravenous), and bortezomib+IL-12 groups. Effects of treatments on tumor growth were assessed by before and after treatment comparisons and group comparisons. The effects of various treatments on the number of peripheral blood lymphocytes and natural killer (NK) cells were assessed by complete blood count and flow cytometry analysis. The cell-killing function of NK cells in splenocytes was evaluated using the lactate dehydrogenase release assay. IL-12 treatment alone produced a mild decrease in tumor volume compared with control (P>0.05). Bortezomib alone resulted in substantial inhibition of tumor growth at varying time points, reaching ∼65 and ∼60% reduction in tumor volume after 15 and 21 days of therapy, respectively. At the same time points, the combination therapy produced ∼75 and ∼84% decreases in tumor growth, respectively, which were significantly greater than the reduction produced by bortezomib monotherapy. Tumors resumed growth upon termination of bortezomib treatment at 2 weeks, although the tumor volume was still significantly smaller than that in the time-matched NS and IL-12 animals. This rebound of tumor growth was completely prevented with the combination therapy, and tumor volume continued to decrease throughout the time course. The percentage and total number of NK cells were significantly decreased after bortezomib monotherapy and combination therapy; however, they remained unaltered after IL-12 treatment compared with no treatment. Further, combination therapy significantly restored the bortezomib-induced functional impairment of the cell-killing capability of NK cells, relative to bortezomib alone. We conclude that the bortezomib−IL-12 combination therapy offers superior antitumor efficacy over monotherapy with either bortezomib or IL-12 in a mouse model of myeloma. Restoration of bortezomib-induced functional impairment of NK cells by IL-12 may be a mechanism for the synergetic effects of the two agents. Therefore, a combination of the two agents may represent a more rational therapeutic approach for myeloma.

23 September 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LSLiu Siquan
Liu Siquan
CWCheng Weilin
Cheng Weilin
CXChen Xiuwen
Chen Xiuwen
ZMZou Meiyan
Zou Meiyan
WGWeihong Guo
Weihong Guo
XFXiaoli Feng
Xiaoli Feng
Nanomaterials (NMs) have extensive application potential in drug delivery, tissue engineering, and various other domains, attributable to their exceptional physical and chemical properties. Nevertheless, an increasing body of literature underscores the diverse safety risks are associated with NMs upon interaction with the human body, including oxidative stress and programmed cell death. Mitochondria, serving as cellular energy factories, play a pivotal role in energy metabolism and the regulation of cell fate. Organs with substantial energy demands, including the heart and brain, are highly sensitive to mitochondrial integrity, with mitochondrial impairment potentially resulting in significant dysfunction and pathologies such as as heart failure and neurodegenerative disease. This review elucidates the pathways by which NMs translocate into mitochondria, their intracellular dynamics, and their impact on mitochondrial morphology, respiratory chain activity, and metabolic processes. We further investigate associated molecular mechanisms, including mitochondrial dynamic imbalance, calcium overload, and oxidative stress, and elucidate the pivotal roles of mitochondria in different forms of programmed cell death such as apoptosis and autophagy. Finally, we offer recommendations regarding the safety and efficacy of NMs for medical applications. By systematically analyzing the interactions and molecular mechanisms between NMs and mitochondria, this paper aims to enhance the toxicological evaluation framework of NMs and provide a foundational reference and theoretical basis for their clinical utilization.

27 September 2021 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
YLYuan Liu
Yuan Liu
LDLianpan Dai
Lianpan Dai
XFXiaoli Feng
Xiaoli Feng
RGRan Gao
Ran Gao
NZNan Zhang
Nan Zhang
MLMinghua Li
Minghua Li
In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection.

1 October 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YLYiheng Luo
Yiheng Luo
XLXundong Lin
Xundong Lin
CSChuyu Su
Chuyu Su
ZZZesen Zheng
Zesen Zheng
YLYuezi Li
Yuezi Li
XFXiaoli Feng
Xiaoli Feng
The rapid development of nanomaterials (NMs) and nanotechnology has profoundly impacted the biomedical field. Due to their unique physicochemical properties, NMs can interact with biological molecules, including proteins and DNA, to induce regulated cell death (RCD). Recent studies have demonstrated that NMs trigger RCD by promoting reactive oxygen species generation, activating signaling proteins, and disrupting intracellular ion homeostasis. Among the various forms of RCD, necroptosis, pyroptosis, ferroptosis, and cuproptosis have garnered significant research attention. Increasing evidence suggests that these emerging RCD pathways are crucial for tumor proliferation and migration, tumor microenvironment (TME) remodeling, and drug resistance mitigation. Accordingly, leveraging NM-driven RCD’s effects in designing multifunctional drug delivery systems holds great promise for cancer therapy. NMs can also serve as versatile drug carriers in synergistic treatments with targeting agents, photothermal/photodynamic therapy, and immunomodulators, thereby overcoming the limitations of conventional treatments. Collectively, this review systematically summarizes recent advancements in NM-induced RCD in cancer cells and discusses the diverse roles of RCD in tumor pathology. We highlight the innovative potential of NMs in inducing RCD through precise targeting and synergistic therapy, offering novel strategies to overcome tumor resistance and reshape the immunosuppressive TME.